Citations

Clear

4 citation(s) found for "Collins, Caden".

A Call for Benzodiazepines in Airline Emergency Medical Kits
Sirven, Joseph I , Collins, Caden , Carrazana, Enrique, Rabinowicz, Adrián L. , Carrazana, Enrique

Mayo Clinic

JAMA Neurology | August 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2787 | PMID 42606845 Get It

This Viewpoint discusses the importance of and considerations for including benzodiazepines in airline emergency medical kits for treating patients who experience seizure during a flight.
Using wearable and nearable devices in telerehabilitation for COPD: a scoping review of digital endpoints in home-based programs
Collins, Caden , Enayati, Moein , Benzo, Roberto, Fortune, Emma , Faust, Louis , Zawada, Stephanie , Benzo, Roberto P.

Mayo Clinic

Frontiers in Digital Health | February 3, 2026 | Volume: 8 | Issue: No issue available | Pages: No page available

10.3389/fdgth.2026.1698019 | PMID 41710266 Get It

Introduction Despite its demonstrated effectiveness at improving outcomes, pulmonary rehabilitation (PR) for chronic obstructive pulmonary disease (COPD) is underutilized. Sensor-generated data from wearable devices have the potential to mitigate this challenge by generating digital endpoints that provide insights into patient behaviors at home; however, there is no consensus on how to measure home-based PR (HBPR) outcomes with these tools. This review aims to describe (1) the most frequent digital endpoints used in HBPR studies and (2) the devices used to capture these endpoints, summarizing gaps in their applications to HBPR for COPD patients. Methods We completed a scoping review using the PRISMA checklist across databases (Web of Science, Scopus, and OVID) from January 1, 2005 to June 1, 2025. We included peer-reviewed articles on HBPR for COPD, excluding reviews, commentaries/editorials, poster abstracts, and conference proceedings. Eligible articles included cohort studies and clinical trials of adult patients (age ≥ 18 years) with COPD participating in HBPR that include one or more digital endpoints. Results Among eligible articles ( n = 218), 13 (6.0%) met inclusion criteria, the majority of which were published after 2020 (61.5%). Most studies enrolled fewer than 100 COPD patients (76.9%) for an average monitoring period of 12.5 weeks. Activity trackers were the most commonly used device (46.2%) to capture data. The most frequently used digital endpoints were step count (84.6%), time spent active (38.5%), and time spent sedentary (30.8%). Two study designs were used: randomized controlled trial (76.9%) and observational cohort. Study designs were heterogenous with more than one-third (38.5%) presenting a lack of statistically significant results. Discussion Although we identified analogous digital endpoints in some studies, dissimilar methods and study designs remain barriers to synthesizing results generated from HBPR programs for COPD. Wearable devices have the potential to build novel PR models, but more work is needed to translate real-world data into clinically meaningful measures. Future research should elucidate which participants would benefit most from and complete HBPR to build an evidence base for the validation of HBPR-relevant digital endpoints, particularly those derived from less common sources like cardiovascular and sleep measures.
Updated multicenter retrospective analysis of systemic treatments in well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Pirozzi, Angelo , Hoyek, Celine , Collins, Caden, Kounsselie, Edwar , Alsulaiman, Abdullah S, Youssef, Amal, Ahn, Daniel H., Bekaii-Saab, Tanios S., Hobday, T., Starr, Jason S., Jamal, Fares , Ahn, Daniel H. , Bekaii‐Saab, Tanios , Hobday, Timothy J. , Starr, Jason S. , Hálfdánarson, Þorvarður R. , McGarrah, Patrick W. , Sonbol, Mohamad Bassam

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 619-619

10.1200/jco.2026.44.2_suppl.619 Get It

619 Background: Well-differentiated G3 GEP-NETs are rare and heterogeneous diseases, limiting phase III trials and definition of clear standards of care. Building upon our preliminary cohort of 76 patients (pts), we present an updated and expanded retrospective analysis across three Mayo Clinic tertiary centers. Methods: We included pts with histologically confirmed well-differentiated G3 GEP-NETs diagnosed since 2017 (new WHO classification) from the three Mayo Clinic sites (Rochester, Phoenix, Jacksonville). Endpoints were ORR, DCR, PFS, and OS across treatment lines. PFS/OS were estimated by Kaplan-Meier. OS was defined from treatment start. Multivariate Cox regression was used to evaluate the association of clinic-pathologic features (age, sex, tumor functionality, Ki-67, primary tumor site, stage at diagnosis, presence of liver metastasis, number of metastatic sites at diagnosis) with OS (p<0.05). Results: 111 pts (median age 62 y, range 22–83). Primary sites were pancreas (58%), small bowel (19%), unknown (9%), and rectum (5%). Most tumors were G3 at diagnosis (88%); the remainder evolved from prior G1/G2. Ki-67 was 20–55% in 83% of cases. Most were nonfunctional (70%); functional subtypes included carcinoid (13%) and gastrinoma (8%). Median plasma 5-HIAA was 38.5 ng/ml (5–1394). Advanced disease was present in 85%. Common metastatic sites included liver (85%), lymph nodes (32%), bone (26%), peritoneum (10%), and lung (9%). Median number of metastatic sites was 1 (range 0–5). Median number of systemic treatment lines was 2 (range 0–8). The most frequent regimens and outcomes are shown in the Table. Insulin-secreting tumors (HR 2.16, 95% CI 1.33–25.73, p=0.019) and ≥2 metastatic sites (HR 2.13, 95% CI 1.05–4.31, p=0.035) were associated with inferior OS. Conclusions: This represents one of the largest real-world datasets of well-differentiated G3 GEP-NETs and provides a deeper evaluation of treatment strategies and prognostic factors. CAPTEM, SSAs, and PRRT with Lu-177 emerged as the most commonly used therapies, with PRRT showing the most favorable outcomes. Insulin secretion and higher metastatic burden were confirmed as adverse prognostic factors. CAPTEM SSAs PRRT Lu-177 Carboplatin plus etoposide FOLFOX Everolimus Sunitinib N of pts (%) 64 (58) 44 (40) 37 (33) 24 (19) 18 (13) 11 (10) 8 (7) Line of therapy (%) First 36 (56.3) 27 (61.4) 5 (13.5) 13 (59.2) 5 (7.2) 1 (9.0) 1 (12.5) Second 15 (23.4) 13 (29.5) 13 (35.2) 3 (13.6) 5 (35.7) 3 (27.3) 2 (37.5) Third or higher 13 (20.3) 4 (9.1) 19 (51.3) 6 (27.2) 8 (57.1) 7 (63.7) 5 (62.5) DCR (%) 60.9 56.8 75.0 52.2 71.4 45.5 37.5 ORR (%) 34.4 13.6 44.4 30.4 35.7 18.2 12.5 mPFS (95% CI) 8.0 (5.3-10.6) 6.2 (2.8-9.5) 11.2 (9.1-13.3) 7.3 (2.8-11.8) 4.4 (2.4-6.4) 3.9 (2.2-5.6) 3.9 (1.54-6.26) mOS (95% CI) 40.1 (23.0-57.2) 50 (22.6-77.4) 76.1 (16.3-135.8) 33.0 (21.0-45.0) 21.1 (15.0-27.2) NE NE
Smartphone Sensor Data May Enhance Real-World Depression Screening in Post-Stroke/TIA Patients (P1-13.008)
Collins, Caden , Dumitrașcu, Oana , Ganjizadeh, Ali , Zawada, Stephanie , Demaerschalk, Bart M. , Erickson, Bradley J.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211006 Get It